2.Recent advances of colony-stimulating factor-1 receptor (CSF-1R) kinase and its inhibitors（2018）3.CSF-1R Inhibitor Development: Current Clinical Status（2017）4.Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R humanized antibody, for Chronic Graft-versus-Host Disease after 2 or ...
研究计划入组约100例受试者,主要终点是基于盲态的独立评审委员会(BIRC)评估的25 周客观缓解率(ORR)。 Milestone — Abbisko Therapeutics Completes the First Patient Dose in US Phase III TGCT Trial of in CSF-1R Inhibitor – Pimicotinib(ABSK021) 2 August 2023, Shanghai – Abbisko Therapeutics Co., ...
2.Recent advances of colony-stimulating factor-1 receptor (CSF-1R) kinase and its inhibitors(2018) 3.CSF-1R Inhibitor Development: Current Clinical Status(2017) 4.Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R humanized antibody, for Chronic Graft-versus-Host Disease after 2 or ...
2.Recent advances of colony-stimulating factor-1 receptor (CSF-1R) kinase and its inhibitors(2018) 3.CSF-1R Inhibitor Development: Current Clinical Status(2017) 4.Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R humanized antibody, for Chronic Graft-versus-Host Disease after 2 or ...
[6] Spangenberg E, et al. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal ...
3.CSF-1R Inhibitor Development: Current Clinical Status(2017) 4.Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R humanized antibody, for Chronic Graft-versus-Host Disease after 2 or more Lines of Systemic Treatment 5.Axatilimab for Chronic Graft-Versus-Host Disease After Failure of...
12 June 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics”hereafter) today announced that the first patient has been dosed in the phase II trial evaluating its CSF-1R inhibitor, Pimicotinib (ABSK021), in patients with cGVHD. ...
S3012PazopanibPazopanib (GW786034) is a novel multi-target inhibitor ofVEGFR1,VEGFR2,VEGFR3, PDGFR, FGFR, c-Kit and c-Fms/CSF1R withIC50of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively. Pazopanib inducescathepsin Bactivation andautophagy. ...
2023 AACR: CT025 - NMS-03592088, a novel, potent FLT3, KIT and CSF1R inhibitor with activity in FLT3 positive acute myeloid leukemia patients with prior FLT3 inhibitor experience责任编辑 | 有点小吴聊 声明本资讯旨在帮助...
顺便提一下,文章称他们的分子为switch-control kinase inhibitor,他们之前有一个上市的KIT抑制剂Ripretinib (DCC-2618),也称为switch-control kinase inhibitor,但感觉就是type Ⅱ inhibitor,也许他们的能更有效地将kinase锁定在inactive状态 (文中提到一两处,...